Summary
Velnacrine is a centrally acting anticholinesterase which has been considered for use in the treatment of Alzheimer’s disease. If proven to be of value, it will be used concurrently with other medications. Its potential to cause interaction is, therefore, important to study. The aim of this work was to investigate velnacrine as an inhibitor of hepatic oxidative enzymes.
The effects of velnacrine on antipyrine metabolism in isolated rat hepatic microsomes were compared to those of cimetidine. Aliquots of 200, 250 and 300 μg/ml antipyrine were incubated alone, with 20 μg/ml cimetidine and with each of 20, 50 and 100 μg/ml velnacrine. The concentrations of antipyrine and of its metabolites, 3-hydroxymethylantipyrine, 4-hydroxyantipyrine and norantipyrine were assayed by reverse phase high performance liquid chromatography. Cimetidine inhibited production of all three metabolites. Velnacrine did not affect 3-hydroxymethylantipyrine production. Mean inhibition of 4-hydroxyantipyrine production of 15%, 30% and 25% (P<0.01), and of 14%, 25% and 12% of norantipyrine production (P<0.01) occurred.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arendt T., Bigl V., Arendt A., Tennstedt A. (1983): Loss of neurons in the nucleus basalis of Meynert in Alzheimer’s disease, paralysis agitans and Korsakoff’s disease. Acta Neuropathol., 61, 101–108.
Candy J.M., Perry E.K. (1983): Pathological changes in the nucleus of Meynert in Alzheimer’s and Parkinson’s diseases. J. Neurol. Sci., 59, 277–289.
Rogers J.D., Brogan D., Mirra S.S. (1985): The nucleus basalis of Meynert in neurological disease: A quantitative morphological study. Ann. Neurol., 17, 163–170.
Whitehouse P.J., Price D.L., Struble R.G. (1986): Alzheimer’s disease and senile dementia: loss of neurons in the basal forebrain. Science, 215, 1237–1239.
Johns C.A., Haroutunian V., Greenwald B.S. (1985): Development of cholinergic drugs for the treatment of Alzheimer’s disease. Drug. Dev. Res., 5, 77–96.
Murphy F.M., Hardiman S.T., Nash R.J., et al. (1991): Evaluation of HP029 (velnacrine maleate) in Alzheimer’s disease. Ann. NY Acad. Sci., 640, 253–262.
Knapp M.J., Knopman D.S., Solomon P.R., Pendlebury W.W., Davis C.S., Gracon S.I. (1994): A 30-week randomised controlled trial of high-dose tacrine in patients with Alzheimer’s disease. JAMA, 271, 985–991.
Spaldin V., Madden S., Pool W.F., Woolf T.F., Park B.K. (1994) The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomes. Br. J. Clin. Pharmacol., 38, 15–22.
Sharer J.E., Wrighton S.A. (1996): Identification of the human hepatic cytochromes P450 involved in the in vitro oxidation of antipyrine. Drug Metab. Dispos., 24, 487–494.
Breimer D.D. (1983): Interindividual variations in drug disposition. Clinical implications and methods of investigation. Clin. Pharmacokinet., 8, 371–377.
Boobis A.R., Sesardic D., Murray B.P., et al. (1990): Species variation in the response of the cytochrome P-450-dependent monooxygenase system to inducers and inhibitors. Xenobiotica, 20, 1139–1161.
Inaba T., Lucassen M., Kalow W. (1980): Antipyrine metabolism in the rat by three hepatic monooxygenases. Life. Sci., 26, 1977–1983.
Rhodes J.C., Hall S.T., Houston J.B. (1984): Inhibition of antipyrine metabolite formation in rats in vivo. Xenobiotica, 14, 677–686.
Somogyi A., Gugler R. (1982): Drug interactions with cimetidine. Clin. Pharmacokinet., 7, 23–41.
Pelkonen O., Puurunen J. (1980): The effect of cimetidine on in vitro and in vivo microsomal drug metabolism in the rat. Biochem. Pharmacol., 29, 3075–3080.
Knodell R.G., Holtzmann J.L., Crankshaw D.L. (1982): Drug metabolism by rat and human hepatic microsomes in response to interactions with histamine H2 antagonists. Gastroenterology, 82, 84–88.
Sorkin E.M., Darvey D.L. (1983): Review of cimetidine drug interactions. Drug Intell. Clin. Pharm., 17, 110–120.
Powell J.R., Donn K.H. (1983): The pharmacokinetic basis for histamine H2 antagonist drug interactions. Concepts and implications. J. Clin. Gastroenterol., 5, 95–113.
Bast A., Savenije-Chapel E.M., Kroes B.H. (1984): Inhibition of mono-oxygenase and oxidase activity of rat hepatic cytochrome P450 by histamine H2 blockers. Xenobiotica, 14, 399–408.
Jensen J.C., Gugler R. (1985): Cimetidine interaction with liver microsomes in vitro and in vivo. Involvement of an activated complex with cytochrome P450. Biochem. Pharmacol., 34, 2141–2146.
Rekka E., Sterk G.J., Timmerman H., Bast, A. (1988): Identification of structural characteristics of some potential histamine H2 antagonists that determine the interaction with rat hepatic P450. Chem. Biol. Interact., 67, 117–127.
Faux S.P., Combes R.D. (1993): Interaction of cimetidine with cytochrome P450 and effect on mixed function oxidase activities of liver microsomes. Hum. Exp. Toxicol., 12, 147–152.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Eccles, M.J., Danbury, T.C., Ford, J.M. et al. The effect of velnacrine on the mixed function oxidase system. European Journal of Drug Metabolism and Pharmacokinetics 22, 121–125 (1997). https://doi.org/10.1007/BF03189794
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF03189794